Are compounded GLP-1 drugs reviewed before sale?

Reviews do not come first for these drugs. The U.S. Food and Drug Administration says "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."

What the missing review means for you

The U.S. Food and Drug Administration draws the risk out directly: "This can be risky for patients, as unapproved versions do not undergo FDA’s review for safety, effectiveness and quality before they are marketed."

Put plainly, the agency's review of safety, effectiveness and quality is absent for these products before sale. Any assurance beyond that has to come from the seller, and you can ask them to show it.

Routine versus a warning sign

A compounded GLP-1 product being offered is something to ask about, not something to accept quietly. A provider who calls it equivalent to an approved drug without explaining who checked it is skipping the step the agency describes.

For background on the condition these drugs are discussed around, read MedlinePlus on obesity and Cleveland Clinic's guide to weight control and obesity.

Before you pay anyone in Ponte Vedra for a compounded GLP-1, ask who reviewed this exact product for safety and quality, and ask to see the answer in writing.